ClinicalTrials.gg
CompletedNCT03574363BLOCKCKDUpdated Dec 30, 2025Results posted

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

A Phase 2 interventional study of KBP-5074 0.25 mg tablet and KBP-5074 0.5 mg tablet in Chronic Kidney Diseases and Hypertension, sponsored by KBP Biosciences. Completed at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by KBP Biosciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
253rd of 819
162 · median 72
Started
2018
with 45 others
Phase 2
156 of 988
21 open now
Registered
545th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 253rd largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2018, is one of 156 in phase 2, and was the 545th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.

Read the detailed description

The study will enroll up to 165 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment groups (55 patients in each group): KBP-5074 0.25 mg once daily (QD), KBP-5074 0.5 mg QD, or placebo QD. Randomization will be stratified to balance enrollment for key variables that may influence safety and/or efficacy evaluations, including estimated Glomerular Filtration Rate (eGFR) (30 versus 29 mL/min/1.73 m2) and Systolic Blood Pressure (SBP) (160 versus \<160 mmHg). The study will be approximately 5 months in duration with 84 days of double-blind treatment. The study will consist of an up to 4-week screening period; 2-week, open-label (placebo) run-in period; 84-day double-blind treatment period; and a 4-week post-treatment safety follow-up period. Patients will be sampled for plasma pharmacokinetics (PK). Total KBP-5074 levels will be assessed in patients treated with active drug. A total of 4 PK samples will be collected from each patient, including Day 1 (prior to discharge), Day 14 pre-dose, Day 28 pre-dose, and End of Study Visit (Day 98)/Early Termination Visit. The pre-dose samples assume that patients will be dosed in the unit on those days above. If patients are not dosed in the unit on those days, a flexible PK sample will be collected during each of these visits.Safety will be assessed systematically, and an independent data monitoring committee will perform cumulative reviews of safety data at regular intervals during the study. Serum potassium levels, serum creatinine, and blood pressure will be closely monitored throughout the study. At Screening, patients must have uncontrolled hypertension, defined as resting trough cuff seated SBP 140 mmHg, based on the mean of the last 2 consecutive blood pressure readings at Screening in the clinic. In all cases, dose and frequency of concurrent antihypertensive medications are expected to be maintained without change for 30 days prior to randomization in order to ensure that blood pressure is stable. In general, patients should not add nor adjust dose and/or types of the antihypertensive medications they are receiving during the screening period and throughout the duration of the study (unless they develop hypertensive crisis or symptomatic hypotension). Patients will be advised to maintain their normal diet and avoid alcohol or potassium-rich foods/drinks during the study period. No potassium supplements are permitted, unless clinically indicated to treat hypokalemia until serum potassium values are within the normal range. Potassium-sparing agents are not permitted. After completion of the screening period and the qualifying Screening Visit, patients who meet all eligibility criteria (except those criteria scheduled to be assessed after the Screening Visit), will enter the 2-week, open-label (placebo) run-in period. At the end of the run-in period, patients will be re-assessed for eligibility, including compliance to study drug received during the run-in period, which must be >80% and 120% (i.e. placebo and stable antihypertensive medication, i.e. no change in antihypertensive medication). If a patient is found to be ineligible during Screening, a 1-time re-screening is allowed if the Investigator believes that the patient's condition has changed and the patient may be eligible before the re-screening tests. Please note that a new patient number should be assigned to any re-screened patient, and all the procedures defined in the protocol for the Screening Visit and during the run-in period must be repeated. Patients who meet all eligibility criteria at the end of the screening period and run-in period will be randomized (stratified based on eGFR 30 versus 29 mL/min/1.73 m2 and SBP 160 versus \<160 mmHg) into the study on Day 1. All randomized patients will receive double-blind treatment for 84 days. Patients will be followed for 4 weeks for safety assessments after the last dose of study drug. A subset of patients who still meet eligibility criteria at the end of the run-in period (Visit 3) will undergo 24-hour ambulatory blood pressure monitoring (ABPM) on Day 1, Day 40, and Day 82.

03

Conditions studied

  • Chronic Kidney Diseases
  • Hypertension

Keywords

  • Chronic Kidney Disease
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, between 18 and 85 years of age, inclusive. The lower age limit may be higher if it is legally required in the participating country;
  2. between 19 and 45 kg/m2, inclusive;
  3. Stage 3B/4 CKD (defined as 15 and 44 mL/min/1.73 m2, based on the isotope dilution mass spectrometry traceable MDRD equation version 4, according to central laboratory results at Screening [single retest is allowed]);
  4. Uncontrolled hypertension (Grade 1 to 2 systolic hypertension - ESC/ESH), defined as:

    • Resting trough cuff seated SBP 140 and 179 mmHg based on the mean of at least 2 current consecutive clinic blood pressure readings at Screening and at the end of the placebo run-in period (Visit 3); AND
    • Currently on 2 or more antihypertensive medications, which have been titrated upward as tolerated to recommended hypertension target doses (such as diuretics [except for potassium-sparing diuretics], renin angiotensin system blockers, and/or calcium channel blockers. One of the antihypertensive medications must be high ceiling diuretic (loop or thiazide like), unless there is a documented intolerance or to diuretic therapy. The doses of the antihypertensive medications should be stable without any dose adjustment during the 30 days prior to randomization; OR
    • Patients with uncontrolled hypertension and moderate-to-severe CKD with documented history of intolerance to multiple antihypertensive medications on fewer than 2 antihypertensive medications;
  5. Serum potassium 4.8 mmol/L at both Screening and the end of the placebo run-in period. A single retest is allowed to exclude laboratory error or hemolyzed samples;
  6. Women of (WOCBP) must agree to use 2 medically accepted, effective methods of during the study and for 90 days after the end of the study. Adequate methods of contraception are defined as those that result in a low failure rate (\< 1% per year) when used consistently and correctly. Such methods include the use of oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products (such as an intrauterine diaphragm, condoms, or spermicides);

    • WOCBP are defined as women who are not surgically or chemically sterilized, including hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable), and who are between menarche and 1-year ; and
    • Post-menopausal is defined as amenorrheic for at least 1 year, AND if aged under 60 years, have a serum follicle-stimulating hormone (FSH) level > 20 mIU/L. Women who are taking hormone replacement therapy (HRT) do not have to have FSH assessments, but the amenorrhea (before starting HRT) must have been naturally (spontaneously) occurring and have been accompanied by an appropriate clinical profile (eg, age appropriate and history of vasomotor symptoms);
  7. Males with partners who are WOCBP must agree to use condoms plus spermicide and their female partner must also be using contraception (eg, hormonal or intra-uterine device). This double contraception must be used from the first dose of study drug until at least 90 days after the last dose of study drug;
  8. Males must also refrain from donating sperm during the study and for 90 days after the last dose; and
  9. Capable of understanding the written , provide signed and witnessed written informed consent before any study-specific procedure, and agree to comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Resting trough seated SBP ≥180 or \< 140 mmHg, based on the mean of at least 2 current consecutive clinic blood pressure readings at Screening and the end of the placebo run-in period (Visit 3);
  2. Serum potassium > 4.8 mmol/L;
  3. Compliance with medications (including both open-label placebo and current antihypertensive medications) \< 80% or > 120% during the run-in period (assessed at Visit 3);
  4. Currently on an MRA (eg, spironolactone or eplerenone) other than KBP-5074, or received any MRAs during the last 3 months prior to Screening, or currently on any potassium supplements;
  5. Chronic or intermittent use of a potassium binder for the treatment of hyperkalemia from 3 months prior to Screening until the end of study assessments, including but not limited to calcium polystyrene sulfonates (eg, sorbisterit, calcium resonium), sodium polystyrene sulfonates (eg, kayexalate, anti-kalium sodium), and patiromer (eg, Veltassa™) and sodium zirconium cyclosilicate (eg, Lokelma™);
  6. Have routinely or chronically used or required potassium-sparing diuretics (eg, amiloride, triamterene) within 3 months prior to Screening until the end of study assessments;
  7. History of known/suspected , allergy, or intolerance to MRAs (eg, spironolactone, eplerenone) or has a known to KBP-5074, other MRAs, or related compounds;
  8. hyperkalemia while on an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, direct renin inhibitor, and/or MRA, requiring down titration or discontinuation of above medication, or hospitalization for hyperkalemia within 3 months prior to Screening, or hyperkalemia > 5.6 mmol/L during the 2 weeks prior to Screening;
  9. History/diagnosis of renal artery stenosis or history/diagnosis of renovascular hypertension;
  10. Currently receiving HD, or peritoneal dialysis within 3 months prior to Screening, and those patients with an episode of acute kidney injury within 3 months of Screening;
  11. History of a renal transplant, or impending renal transplant;
  12. Acute decompensated heart failure including exacerbation of chronic heart failure manifested by signs and symptoms that may require hospitalization and/or intravenous diuretic therapy ( Class III to IV) within 3 months prior to Screening, or presence of hemodynamically significant valve diseases and/or other hemodynamically significant obstructive lesions of left ventricular outflow tract;
  13. Major cardiac, cerebral, and/or carotid artery diseases, including but not limited to acute coronary syndrome, myocardial infarction, stroke, and/or ; major cardiovascular or percutaneous procedures including cardiac ablation, coronary revascularization, and carotid angioplasty within 6 months prior to Screening; OR

    - Cardiovascular conditions likely to require surgical or percutaneous intervention within 6 months from Screening;

  14. History of clinically significant arrhythmia, including but not limited to any of the following:

    • Symptomatic bradycardia and/or symptomatic ventricular arrhythmia within 3 months prior to Screening;
    • Second- or third-degree heart block; or
    • New onset or untreated atrial fibrillation; Note: Patients with stable (6 months) asymptomatic rate controlled atrial fibrillation on appropriate therapy, which may include anticoagulation, are permitted.
  15. corrected using Fridericia's formula (QTcF) > 450 ms for males or > 470 ms for females at Screening or Day 1; QTcF should be the average of the required triplicate set of ECGs at each timepoint;
  16. History of prolonged QT interval;
  17. History or family history of sudden cardiac death or long QT syndrome;
  18. History of cardiac transplant, on a heart transplant list, or has a left ventricular assistance device;
  19. History of clinically significant acute or chronic hepatitis (including infectious, metabolic, , genetic, ischemic, or other forms), hepatocirrhosis, or hepatic tumors;
  20. History of gastrointestinal surgery that might affect absorption/oral bioavailability of oral antihypertensive therapies including KBP-5074;
  21. Clinically significant abnormal liver function test at Screening or the end of the run-in period (Visit 3), defined as or alanine aminotransferase > 3 × the (ULN) or total > 2 × ULN;

    • Note: Patients with total bilirubin > 2 × ULN and history of Gilbert's syndrome may be included.
  22. Positive blood screen for (HIV), surface antigen (HbsAg), or virus (HCV) antibody;
  23. History of in the past 5 years, with the exception of basal or resected cutaneous squamous cell carcinoma of the skin or carcinoma in situ, prostate cancer in situ with a normal prostate-specific antigen post treatment, cervical carcinoma in situ, gastric cancer in situ, colon cancer in situ adequately treated with no progression over the past 2 years;
  24. History of prescription drug abuse, illicit drug use, or alcohol abuse according to medical history within 6 months prior to Screening;
  25. A positive drug screen test (excluding a positive result secondary to a prescribed medication from a physician, or tetrahydrocannabinol) at Screening or the end of the run-in period (Visit 3);
  26. Female patients who are known to be pregnant or breastfeeding;
  27. Previously enrolled in any KBP-5074 study;
  28. Receipt of any other product within 30 days or 5 half-lives (whichever is longer) prior to Screening;
  29. Use of any nutrients known to modulate cytochrome P450 (CYP)3A activity (based on the KBP-5074 metabolic pathway) or any strong or moderate inhibitors or inducers of , starting from 14 days prior to the first dose of study drug at Day 1 until the end of study assessments, including but not limited to the following: inhibitors, such as ketoconazole, miconazole, itraconazole, fluconazole, atazanavir, erythromycin, clarithromycin, ranitidine, and cimetidine, and inducers, such as rifampicin, rifabutin, , carbamazepine, phenytoin, phenobarbital, and St. John's wort;
  30. Has donated or lost a significant volume (> 500 mL) of blood or plasma within 30 days prior to Screening;
  31. An employee or family member of the Investigator or study site personnel;
  32. Unlikely to comply with the protocol requirements, instructions, and/or study-related restrictions (eg, uncooperative attitude, unavailable for follow up call, and/or improbability of completing the clinical study); and
  33. History of any other prior or concomitant clinical condition or acute and/or unstable systemic disease not listed above that, in the opinion of the Investigator, compromises patient inclusion, such as a history or presence of clinically decompensated or unstable cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, or concomitant morbidity of such severity that the patient is likely to die within 1 year from Screening.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    KBP-5074 0.25 mg tablet

    KBP-5074 0.25 mg tablet QD orally, 84 days

    Drug: KBP-5074 0.25 mg tablet

  • Experimental
    KBP-5074 0.5 mg tablet

    KBP-5074 0.5 mg tablet QD orally, 84 days

    Drug: KBP-5074 0.5 mg tablet

  • Placebo comparator
    Placebo tablet

    Placebo tablet QD orally, 84 days

    Drug: KBP-5074 0.25 mg tablet · Drug: KBP-5074 0.5 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure

    Change in trough cuff resting seated SBP from baseline to Day 84.

    Time frame: Baseline to Day 84

Secondary outcomes

  1. Diastolic Blood Pressure

    Change in trough cuff seated DBP from baseline to Day 84

    Time frame: Baseline to Day 84

  2. UACR

    Change in UACR from baseline to Day 84

    Time frame: Baseline to Day 84

Other outcomes

  1. Total KBP-5074 Concentration

    Total KBP-5074 concentration

    Time frame: Day 84

07

Results

Posted Mar 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneKBP-5074 .25mgKBP-5074 .5mgPlacebo
Started515457
Completed474447
Not completed41010

Outcome measures

PrimarySystolic Blood Pressure

Change in trough cuff resting seated SBP from baseline to Day 84.

Time frame:
Baseline to Day 84
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHgPlacebo TabletKBP-5074 0.25 mg TabletKBP-5074 0.5 mg Tablet
Baseline155.8 ± 1.44154.3 ± 2.11155.7 ± 2.01
Day 84150.4 ± 1.98142.8 ± 2.65139.9 ± 2.65
Change from Baseline to Day 84-5.3 ± 2.39-11.5 ± 2.9-15.9 ± 3.15
SecondaryDiastolic Blood Pressure

Change in trough cuff seated DBP from baseline to Day 84

Time frame:
Baseline to Day 84
Reported as:
Mean · mmHg
Diastolic Blood Pressure
mmHgPlacebo TabletKBP-5074 0.25 mg TabletKBP-5074 0.5 mg Tablet
Baseline85.9 ± 1.5289 ± 1.788.4 ± 1.78
Day 8483.8 ± 1.3482.2 ± 1.6881.4 ± 1.90
Change from Baseline to Day 84-2.0 ± 1.41-6.7 ± 2.02-7.0 ± 2.23
SecondaryUACR

Change in UACR from baseline to Day 84

Time frame:
Baseline to Day 84
Reported as:
Geometric mean · mg/g
UACR
mg/gPlacebo TabletKBP-5074 0.25 mg TabletKBP-5074 0.5 mg Tablet
Baseline483.7038 (288.6661 to 810.5189)700.4447 (465.8093 to 1053.2694)519.0621 (328.9336 to 819.0876)
Day 84313.91930 (160.8878 to 612.5096)435.7897 (256.8354 to 739.4333)372.0062 (217.4223 to 636.4968)
Change from Baseline to Day 840.6927 (0.4868 to 0.9858)0.6222 (0.3590 to 1.0781)0.7328 (0.4774 to 1.1249)
Other pre-specifiedTotal KBP-5074 Concentration

Total KBP-5074 concentration

Time frame:
Day 84

Results for this outcome have not been posted.

Adverse events

Collected over AE collection started with the signing of the ICF followed by 4 weeks of screening period, then 2 weeks of run-in period, then 84 days of double-blind study treatment, then 4 weeks of safety follow up. Total AE collection period was 22 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Tablet2/57 (3.5%)4/57 (7%)15/57 (26.3%)
KBP-5074 0.25 mg Tablet0/51 (0%)1/51 (2%)20/51 (39.2%)
KBP-5074 0.5 mg Tablet0/54 (0%)2/54 (3.7%)34/54 (63%)
Most frequent serious events
Most frequent serious events
EventPlacebo TabletKBP-5074 0.25 mg TabletKBP-5074 0.5 mg Tablet
Cerebrovascular accidentNervous system disorders0/571/510/54
Myocardial infarctionCardiac disorders1/570/511/54
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/511/54
Gastric ulcer hemorrhageGastrointestinal disorders1/570/510/54
pneumoniaInfections and infestations1/570/510/54
DeathGeneral disorders1/570/510/54
Most frequent other events
Most frequent other events
EventPlacebo TabletKBP-5074 0.25 mg TabletKBP-5074 0.5 mg Tablet
HyperkalemiaMetabolism and nutrition disorders14/5715/5128/54
eGFR decreaseInvestigations0/573/510/54
CKDRenal and urinary disorders1/572/513/54
HypotensionVascular disorders0/570/512/54
renal failureRenal and urinary disorders0/570/511/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)KBP-5074 .25mgKBP-5074 .5mgPlaceboTotal
<=18 years0000
Between 18 and 65 years23242774
>=65 years28303088
Sex: Female, Male
Sex: Female, Male(Participants)KBP-5074 .25mgKBP-5074 .5mgPlaceboTotal
Female27232373
Male24313489
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KBP-5074 .25mgKBP-5074 .5mgPlaceboTotal
Hispanic or Latino1281535
Not Hispanic or Latino394642127
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KBP-5074 .25mgKBP-5074 .5mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American55212
White464954149
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)KBP-5074 .25mgKBP-5074 .5mgPlaceboTotal
North America18182056
Europe313436101
Chile1203
Israel1012
08

Study locations

2 sites
  • KBP Biosciences USA Inc
    Princeton, New Jersey 08540, United States
  • Worldwide Clinical Trials
    Morrisville, North Carolina 27560, United States
09

References and documents

Publications

  • Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B; BLOCK-CKD Study Group. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 Jul;78(1):74-81. doi: 10.1161/HYPERTENSIONAHA.121.17073. Epub 2021 May 10. PubMed 33966452 ↗
  • Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 Jul;76(1):144-149. doi: 10.1161/HYPERTENSIONAHA.120.15199. Epub 2020 Jun 10. PubMed 32520623 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2020, 27 months.

Results were first posted in Mar 2024, 3 years 7 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2018
First posted
Jul 2, 2018
StartActual
Apr 25, 2018
Primary completionActual
Aug 5, 2020
CompletionActual
Aug 5, 2020
Results first posted
Mar 21, 2024
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03574363
Lead sponsor
KBP Biosciences
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Jul 2, 2018
Start date
Apr 25, 2018
Primary completion
Aug 5, 2020
Completion
Aug 5, 2020
Results posted
Mar 21, 2024
Last update
Dec 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion